While TR 27 is still a valuable educational tool, professionals in the field are advised to stay informed about the pending update, which will reflect the current state of regulatory science and industry practice.
Package integrity is not a one-time test; it is an ongoing process. TR 27 details how to assess and maintain CCI during:
PDA Technical Report No. 27, "Pharmaceutical Package Integrity," provides comprehensive guidance on Container Closure Integrity Testing (CCIT) to ensure the barrier quality of pharmaceutical packaging, particularly for sterile products. It outlines strategies for establishing integrity standards and selecting appropriate test methods, such as helium mass spectrometry and microbial challenge, throughout the product lifecycle. The full report is available for purchase at the PDA Bookstore . Technical Report No. 27: Pharmaceutical Package Integrity pda technical report 27 pdf
“TR 27 says dye ingress is dead.” Reality: TR 27 states dye ingress is a “coarse leak test” suitable for quality control sampling, but it is not sensitive enough for small molecule or biologic products that require <1 µm integrity.
This adoption by global authorities underscores the report's role as an international scientific standard, even though it is nearly three decades old. It has shaped the thinking of regulators and industry professionals on the critical aspects of ensuring sterility through proper packaging. While TR 27 is still a valuable educational
TR 27 categorizes package integrity testing into distinct modalities, laying the groundwork for the modern distinction between probabilistic and deterministic methods. 1. Microbial Ingress Testing (Probabilistic)
You must have an account to complete the purchase. After purchasing, you will receive a for download. If you require multi-user licensing for a team, you should contact PDA directly at info@pda.org. Technical Report No
PDA Technical Report No. 27, titled Pharmaceutical Package Integrity , was published by the Parenteral Drug Association (PDA) in April 1998. This 48-page report was prepared by the PDA Task Force on Container/Closure Integrity and supersedes the earlier PDA Technical Information Bulletin No. 4 on the same subject. While it addresses the complexity of all pharmaceutical products and packages, its primary emphasis is on packaging intended for , making it a critical resource for manufacturers of injectable drugs and other sterile dosage forms.
: Immersing filled containers into a highly concentrated bacterial suspension to see if bacteria break through the seal over time.